Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

27th May 2021 14:11

RNS Number : 0819A
Vectura Group plc
27 May 2021
 

Vectura Group plc

 

Appointment of Senior Independent Director

 

Chippenham, UK - 27 May 2021: Vectura Group plc (LSE: V EC) ("Vectura" or "the Group") announces that, as reported in our 2020 Annual Report and Accounts, following the Annual General Meeting Dr Thomas Werner stepped down as a Non-Executive Director and the Senior Independent Director, roles he has held since 2009 and 2019 respectively.

 

With effect from the close of the Annual General Meeting, Jeanne Thoma has been appointed as the Senior Independent Director of the Company.

 

Bruno Angelici, Chairman of the Board, said: "Thomas' contribution, initially to Skyepharma and later to Vectura, has been remarkable. His deep experience and business judgement will be missed. We are delighted that Jeanne Thoma will be taking up the role as the new Senior Independent Director."

 

- Ends-

 

For more information, please contact:

 

Vectura Group plc

John Murphy - Company Secretary +44 (0)207 881 1206

Olivia Manser - Director, Investor Relations +44 (0)7947 758 259

David Ginivan - VP Corporate Communications +44 (0)7471 352 720

 

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Melissa Gardiner / David Daley

 

About Vectura

Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has twelve key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAXDLFLFELBBBQ

Related Shares:

VEC.L
FTSE 100 Latest
Value8,275.66
Change0.00